Effect of preventive treatment with atogepant on quality of life, daily functioning, and headache impact across the spectrum of migraine: Findings from three double-blind, randomized, phase 3 trials
Preventive migraine treatment with atogepant 60 mg once-daily vs. placebo improved measures of migraine-related quality of life and functioning among participants with different headache frequencies and histories of previous treatment failure.<b>Trial Registration:</b> ClinicalTrials.gov: NCT03777059 (ADVANCE); NCT03855137 (PROGRESS); NCT04740827 (ELEVATE).
Authors
- Richard B. Lipton (ORCID: https://orcid.org/0000-0003-2652-2897)
- Pranav Gandhi (ORCID: https://orcid.org/0009-0008-8317-7712)
- Patricia Pozo‐Rosich (ORCID: https://orcid.org/0000-0003-0796-4702)
- Krisztián Nagy (ORCID: https://orcid.org/0000-0002-6935-0995)
- Cristina Tassorelli (ORCID: https://orcid.org/0000-0003-1513-2113)
- Joel M. Trugman (ORCID: https://orcid.org/0000-0002-2376-8878)
- Yingyi Liu (ORCID: https://orcid.org/0000-0003-2394-5106)
- Suzanne Christie
- Lei Luo (ORCID: https://orcid.org/0000-0001-8235-351X)
- Christopher Gottschalk (ORCID: https://orcid.org/0000-0003-4584-0014)
- Jonathan Stokes
Institutions
- Hebron University (PS)
- Universitat Autònoma de Barcelona (ES)
- Albert Einstein College of Medicine (US)
- University of Ottawa (CA)
- University of Pavia (IT)
- AbbVie (United States) (US)
- Yale University (US)
- Vall d'Hebron Institut de Recerca (ES)
- Vall d'Hebron Hospital Universitari (ES)
Publication Details
- Journal
- Cephalalgia
- Published
- 2024-12-01
- DOI
- https://doi.org/10.1177/03331024241300305
- Citations
- 2
- Primary Topic
- Migraine and Headache Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.77
Funders
- AbbVie